Robbins Arroyo LLP Announces Top Ongoing Investigations

Shareholder rights law firm Robbins Arroyo LLP highlights for investors its top ongoing investigations. Investors who would like more information regarding the firm’s investigations and findings in regard to SeaWorld Entertainment, Inc., World Wrestling Entertainment, Inc., Impax Laboratories, Inc., Cobalt International Energy, Inc., and Regeneron Pharmaceuticals, Inc. are urged to contact attorney Darnell R. Donahue at (800) 350-6003. Highlights from each investigation are noted below.

SeaWorld Entertainment, Inc. (SEAS)

The SeaWorld Entertainment, Inc. (NYSE:SEAS) investigation arises from a federal securities fraud class action complaint filed in the U.S. District Court for the Southern District of California, against SeaWorld and on behalf of all persons who purchased or otherwise acquired SeaWorld securities between April 18, 2013 and August 13, 2014. The complaint and investigation focus on allegations that SeaWorld’s registration statement for its initial public offering was materially false and misleading due to its failure to disclose that the company mistreated its Ocras, put its employees in danger by forcing them to work with highly stressed Ocras, and that these actions could negatively impact attendance at its parks.

World Wrestling Entertainment, Inc. (WWE)

On July 25, 2014, Robbins Arroyo LLP filed a federal securities fraud class action lawsuit in the U.S. District Court for the District of Connecticut against World Wrestling Entertainment, Inc. (NYSE:WWE) (“WWE”) on behalf of all persons who purchased or otherwise acquired WWE securities between October 31, 2013 and May 16, 2014. The complaint alleges that during the class period, WWE issued a series of false and misleading statements regarding the company’s ability to command a premium fee in upcoming negotiations to renew its television license agreement that adversely affected shareholders.

Impax Laboratories, Inc. (IPXL)

The Impax Laboratories, Inc. (NASDAQ: IPXL) investigation focuses on whether officers and directors at the company breached their fiduciary duties to shareholders by failing to correct the company’s inadequate quality controls and deficiencies in its manufacturing processes. Indeed, multiple U.S. Food and Drug Administration on-site inspections of Impax’s Hayward, California manufacturing facility released significant violations of Current Good Manufacturing Practice regulations for Finished Pharmaceuticals.

Cobalt International Energy, Inc. (CIE) and Regeneron Pharmaceuticals, Inc. (REGN)

Robbins Arroyo LLP’s Cobalt International Energy, Inc. (NYSE: CIE) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) investigations focus on whether certain officers and directors at both companies breached their fiduciary duties to shareholders.

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, or you can complete the form below and we will contact you directly.

 

Shareholder Information

Items marked with an asterisk (*) are required information.

First Name * Last Name *
Address City State/Province *
ZIP/Postal Code Country/Region Phone *
E-mail * Confirm: E-mail *

Shares Purchased:
Number of Shares: Buy Date : Price Per Share:
example: 125 example: MM/DD/YYYY example: 30.00
transaction:
transaction:
transaction:
transaction:
transaction:
If you have additional transactions or comments, please input the information below:

Shares Sold:
Number of Shares: Buy Date : Price Per Share:
example: 125 example: MM/DD/YYYY example: 30.00
transaction:
transaction:
transaction:
transaction:
transaction:
If you have additional transactions or comments, please input the information below:

Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

* I have read the disclaimer information
+=

    Send This Post

    Tags: